What role do cannabinoids have in modern medicine as gastrointestinal anti-inflammatory drugs?

References

• Nemati S, Teimourian S. An overview of inflammatory bowel disease: general consideration and genetic screening approach in diagnosis of early onset subsets. Middle East J Dig Dis. 2017;9:69–80.
   PubMedGoogle Scholar
• Atakan Z. Cannabis, a complex plant: different compounds and different effects on individuals. Ther Adv Psychopharmacol. SAGE Publications. 2012;2(6):241–254
   PubMedGoogle Scholar
• Freeman TP, Hindocha C, Green SF, et al. Medicinal use of cannabis based products and cannabinoids. BMJ. 2019 Apr 4;365:l1141. DOI:10.1136/bmj.l1141.
   PubMed Web of Science ®Google Scholar
• Hazekamp A, Ware MA, Muller-Vahl KR, et al. The medicinal use of cannabis and cannabinoids-an international cross-sectional survey on administration forms. J Psychoactive Drugs. 2013;45:199–210.
   PubMed Web of Science ®Google Scholar
• Hasenoehrl C, Storr M, Schicho R. Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go? Expert Rev Gastroenterol Hepatol. 2017;11:329–337.
   Web of Science ®Google Scholar
• Massa F, Marsicano G, Hermann H, et al. The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest. 2004;113:1202–1209.
   PubMed Web of Science ®Google Scholar
• D’Argenio G, Valenti M, Scaglione G, et al. Up‐regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. Faseb J. 2006;20:568–570.
   PubMed Web of Science ®Google Scholar
• Storr MA, Keenan CM, Emmerdinger D, et al. Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors. J Mol Med. 2008;86:925–936.
   PubMed Web of Science ®Google Scholar
• Grill M, Högenauer C, Blesl A, et al. Members of the endocannabinoid system are distinctly regulated in inflammatory bowel disease and colorectal cancer. Sci Rep. 2019;9:1–13.
   PubMed Web of Science ®Google Scholar
• Ambrose T, Simmons A. Cannabis, Cannabinoids, and the endocannabinoid system-is there therapeutic potential for inflammatory bowel disease? J Crohns Colitis. 2019;13:525–535.
   PubMed Web of Science ®Google Scholar
• Sharkey KA, Wiley JW. The role of the endocannabinoid system in the Brain–Gut Axis. Gastroenterology. W.B. Saunders. 2016;151(2):252–266.
   PubMed Web of Science ®Google Scholar
• Izzo AA, Camilleri M. Cannabinoids in intestinal inflammation and cancer. Pharmacol Res. 2009;60:117–125.
   PubMed Web of Science ®Google Scholar
• Leinwand KL, Gerich ME, Hoffenberg EJ, et al. Manipulation of the endocannabinoid system in colitis: a comprehensive review. Inflamm Bowel Dis. Lippincott Williams and Wilkins. 2017;23(2):192–199
   PubMed Web of Science ®Google Scholar
• Muccioli GG, Naslain D, Bäckhed F, et al. The endocannabinoid system links gut microbiota to adipogenesis. Mol Syst Biol. 2010;6:392.
   PubMed Web of Science ®Google Scholar
• Rousseaux C, Thuru X, Gelot A, et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med. 2007;13:35–37.
   PubMed Web of Science ®Google Scholar
• Mehrpouya-Bahrami P, Chitrala KN, Ganewatta MS, et al. Blockade of CB1 cannabinoid receptor alters gut microbiota and attenuates inflammation and diet-induced obesity. Sci Rep. 2017;7:1–16.
   PubMed Web of Science ®Google Scholar
• McVey DC, Schmid PC, Schmid HHO, et al. Endocannabinoids induce ileitis in rats via the capsaicin receptor (VR1). J Pharmacol Exp Ther. 2003;304:713–722.
   PubMed Web of Science ®Google Scholar
• Kienzl M, Storr M, Schicho R. Cannabinoids and opioids in the treatment of inflammatory bowel diseases. Clin Transl Gastroenterol. 2020;11:e00120.
   PubMed Web of Science ®Google Scholar
• Weiss A, Friedenberg F. Patterns of cannabis use in patients with inflammatory bowel disease: a population based analysis. Drug Alcohol Depend. 2015;156:84–89.
   PubMed Web of Science ®Google Scholar
• Lahat A, Lang A, Shomron BH. Impact of cannabis treatment on the quality of life, weight and clinical disease activity in inflammatory bowel disease patients: A pilot prospective study. Digestion. 2012;85(1):1–8.
   PubMed Web of Science ®Google Scholar
• Naftali T, Bar-Lev Schleider L, Dotan I, et al. Cannabis induces a clinical response in patients with Crohn’s disease: a prospective placebo-controlled study. Clin Gastroenterol Hepatol. 2013;11:1276–1280.
   PubMed Web of Science ®Google Scholar
• Irving PM, Iqbal T, Nwokolo C, et al. A randomized, double-blind, placebo-controlled, parallel-group, pilot study of cannabidiol-rich botanical extract in the symptomatic treatment of ulcerative colitis. Inflamm Bowel Dis. 2018;24:714–724.
   PubMed Web of Science ®Google Scholar
• Schicho R, Storr M. Topical and systemic cannabidiol improves trinitrobenzene sulfonic acid colitis in mice. Pharmacology. 2012;89:149–155.
   PubMed Web of Science ®Google Scholar
• Esposito G, De Filippis D, Cirillo C, et al. Cannabidiol in inflammatory bowel diseases: A brief overview. Phyther Res. 2013;27(5):633–636.
   PubMed Web of Science ®Google Scholar
• Naftali T, Mechulam R, Marii A, et al. Low-dose cannabidiol is safe but not effective in the treatment for Crohn’s disease, a randomized controlled trial. Dig Dis Sci. 2017;62:1615–1620.
   PubMed Web of Science ®Google Scholar
• Storr M, Devlin S, Kaplan GG, et al. Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn’s disease. Inflamm Bowel Dis. 2014;20:472–480.
   PubMed Web of Science ®Google Scholar
• Lal S, Prasad N, Ryan M, et al. Cannabis use amongst patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2011;23:891–896.
   PubMed Web of Science ®Google Scholar
• Wang T, Collet JP, Shapiro S, et al. Adverse effects of medical cannabinoids: A systematic review. Cmaj Cmaj. 2008;178(13):1669–1678.
   PubMed Web of Science ®Google Scholar
• Devinsky O, Marsh E, Friedman D, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016;15(3):270–278.
   PubMed Web of Science ®Google Scholar
• Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391:1085–1096.
   PubMed Web of Science ®Google Scholar
• Alatab S, Sepanlou SG, Ikuta K, et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol. 2020;5:17–30.
   PubMed Web of Science ®Google Scholar
• Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: A systematic review and meta-analysis. J Am Med Assoc. American Medical Association. 2015;313(24):2456–2473.
   PubMed Web of Science ®Google Scholar